Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety and Tolerability Study of 45 mg Pioglitazone in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)

NCT00690118 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT00690118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00690118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety and Tolerability Study of 45 mg Pioglitazone in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)
Lead sponsor
University of Ulm
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2008
Completion date
June 30, 2010
Enrollment
219 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis